Seminal pharmaceutical trials: Maintaining masking in analysis

Lancet

Volumn 360, Issue 9327, 2002, Pages 100-101

  Boers, Maarten ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CORTISONE; ROFECOXIB; STREPTOMYCIN;

CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DRUG INDUSTRY; DRUG RESEARCH; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HUMAN; NOTE; PRIORITY JOURNAL; QUALITY CONTROL; RHEUMATOLOGY;

EID: 0037072085     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09436-9     Document Type: Note

References (15)

1. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
2. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial
3. NSAIDs and selective Cox-2 inhibitors: Competition between gastroprotection and cardioprotection
4. Industry-sponsored clinical research: A double-edged sword
5. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib
6. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
7. Risk of cardiovascular events associated with selective COX-2 inhibitors
8. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
9. The risk of cardiovascular thrombotic events with cox-2 selective inhibitors
10. The clinical trial: Deceitful, disputable, unbelievable, unhelpful, and shameful - What next?
11. Sponsorship, authorship, and accountability
12. Blinding during data analysis and writing of manuscripts